IDT CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IDT CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.23B | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $1.21B | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $1.24B | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $1.36B | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $1.45B | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | $1.35B | Oct 14, 2022 |
| FY2019 | Jul 31, 2019 | $356.13M | Oct 11, 2019 |
| FY2019 | Apr 30, 2019 | $341.26M | Oct 11, 2019 |
| FY2019 | Jan 31, 2019 | $349.47M | Oct 11, 2019 |
| FY2019 | Oct 31, 2018 | $362.32M | Oct 11, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $446.20M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $390.16M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $357.24M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $325.00M | Oct 15, 2024 |
| FY2012 | Jul 31, 2012 | $237.36M | Nov 9, 2012 |
| FY2012 | Jul 31, 2011 | $232.25M | Nov 9, 2012 |
| FY2012 | Jul 31, 2010 | $226.39M | Nov 9, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $76.09M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $64.45M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $40.49M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $27.03M | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $96.48M | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | $21.43M | Oct 14, 2022 |
| FY2019 | Jul 31, 2019 | $1.57M | Oct 11, 2019 |
| FY2019 | Apr 30, 2019 | $2.17M | Oct 11, 2019 |
| FY2019 | Jan 31, 2019 | ($1.31M) | Oct 11, 2019 |
| FY2019 | Oct 31, 2018 | ($2.30M) | Oct 11, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $100.42M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $64.75M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $60.74M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $60.09M | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $56.99M | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | $17.94M | Oct 14, 2022 |
| FY2019 | Jul 31, 2019 | ($1.18M) | Oct 11, 2019 |
| FY2019 | Apr 30, 2019 | $449.0K | Oct 11, 2019 |
| FY2019 | Jan 31, 2019 | ($457.0K) | Oct 11, 2019 |
| FY2019 | Oct 31, 2018 | $182.0K | Oct 11, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $50.96M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $50.55M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $47.99M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $47.05M | Oct 15, 2024 |
| FY2017 | Jul 31, 2015 | $1.66M | Oct 16, 2017 |
| FY2016 | Jul 31, 2014 | $10.02M | Oct 14, 2016 |
| FY2015 | Jul 31, 2013 | $7.17M | Oct 14, 2015 |
| FY2014 | Jul 31, 2012 | $4.57M | Oct 14, 2014 |
| FY2013 | Jul 31, 2011 | $2.83M | Oct 15, 2013 |
| FY2012 | Jul 31, 2010 | $2.78M | Nov 9, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $287.57M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $270.21M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $243.16M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $216.92M | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $218.47M | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | $214.85M | Oct 14, 2022 |
| FY2020 | Jul 31, 2019 | $204.37M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $203.25M | Oct 11, 2019 |
| FY2019 | Jul 31, 2017 | $188.29M | Oct 11, 2019 |
| FY2018 | Jul 31, 2016 | $204.66M | Oct 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $127.06M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $78.19M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $52.40M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $29.41M | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $66.62M | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | ($29.59M) | Oct 14, 2022 |
| FY2020 | Jul 31, 2019 | $85.14M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $20.39M | Oct 11, 2019 |
| FY2019 | Jul 31, 2017 | $36.09M | Oct 11, 2019 |
| FY2018 | Jul 31, 2016 | $49.05M | Oct 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $20.77M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $18.92M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $21.96M | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | $21.88M | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | $16.77M | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | $16.04M | Oct 14, 2022 |
| FY2020 | Jul 31, 2019 | $18.68M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $20.57M | Oct 11, 2019 |
| FY2019 | Jul 31, 2017 | $22.95M | Oct 11, 2019 |
| FY2018 | Jul 31, 2016 | $18.37M | Oct 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $626.20M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $550.10M | Sep 29, 2025 |
| FY2024 | Jul 31, 2023 | $510.81M | Oct 15, 2024 |
| FY2023 | Jul 31, 2022 | $497.09M | Oct 16, 2023 |
| FY2022 | Jul 31, 2021 | $512.66M | Oct 14, 2022 |
| FY2021 | Jul 31, 2020 | $404.75M | Oct 14, 2021 |
| FY2020 | Jul 31, 2019 | $443.70M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $399.60M | Oct 11, 2019 |
| FY2019 | Jul 31, 2017 | $518.96M | Oct 11, 2019 |
| FY2018 | Jul 31, 2016 | $469.66M | Oct 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $295.79M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $283.54M | Sep 29, 2025 |
| FY2024 | Jul 31, 2023 | $300.34M | Oct 15, 2024 |
| FY2023 | Jul 31, 2022 | $316.27M | Oct 16, 2023 |
| FY2022 | Jul 31, 2021 | $346.04M | Oct 14, 2022 |
| FY2021 | Jul 31, 2020 | $333.61M | Oct 14, 2021 |
| FY2020 | Jul 31, 2019 | $390.15M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $368.29M | Oct 11, 2019 |
| FY2018 | Jul 31, 2017 | $364.41M | Oct 15, 2018 |
| FY2017 | Jul 31, 2016 | $345.46M | Oct 16, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $305.13M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $246.18M | Sep 29, 2025 |
| FY2024 | Jul 31, 2023 | $193.73M | Oct 15, 2024 |
| FY2023 | Jul 31, 2022 | $167.62M | Oct 16, 2023 |
| FY2022 | Jul 31, 2021 | $164.86M | Oct 14, 2022 |
| FY2021 | Jul 31, 2020 | $74.77M | Oct 14, 2021 |
| FY2020 | Jul 31, 2019 | $56.24M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $30.66M | Oct 11, 2019 |
| FY2018 | Jul 31, 2017 | $145.73M | Oct 15, 2018 |
| FY2017 | Jul 31, 2016 | $123.80M | Oct 16, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $26.49M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $26.29M | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | $26.46M | Sep 29, 2025 |
| FY2025 | Jul 31, 2022 | $26.38M | Sep 29, 2025 |
| FY2024 | Jul 31, 2021 | $14.90M | Oct 15, 2024 |
| FY2023 | Jul 31, 2020 | $12.86M | Oct 16, 2023 |
| FY2022 | Jul 31, 2019 | $11.21M | Oct 14, 2022 |
| FY2020 | Jul 31, 2018 | $11.32M | Oct 14, 2020 |
| FY2018 | Jul 31, 2017 | $11.33M | Oct 15, 2018 |
| FY2017 | Jul 31, 2016 | $11.22M | Oct 16, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $157.12M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $86.58M | Sep 29, 2025 |
| FY2024 | Jul 31, 2023 | $24.66M | Oct 15, 2024 |
| FY2023 | Jul 31, 2022 | ($15.83M) | Oct 16, 2023 |
| FY2022 | Jul 31, 2021 | ($42.86M) | Oct 14, 2022 |
| FY2021 | Jul 31, 2020 | ($139.33M) | Oct 14, 2021 |
| FY2020 | Jul 31, 2019 | ($160.76M) | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | ($173.10M) | Oct 11, 2019 |
| FY2018 | Jul 31, 2017 | ($163.37M) | Oct 15, 2018 |
| FY2017 | Jul 31, 2016 | ($153.67M) | Oct 16, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $226.51M | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | $164.56M | Sep 29, 2025 |
| FY2024 | Jul 31, 2023 | $103.64M | Oct 15, 2024 |
| FY2023 | Jul 31, 2022 | $98.35M | Oct 16, 2023 |
| FY2022 | Jul 31, 2021 | $107.15M | Oct 14, 2022 |
| FY2021 | Jul 31, 2020 | $84.86M | Oct 14, 2021 |
| FY2020 | Jul 31, 2019 | $80.17M | Oct 14, 2020 |
| FY2019 | Jul 31, 2018 | $73.98M | Oct 11, 2019 |
| FY2018 | Jul 31, 2017 | $90.34M | Oct 15, 2018 |
| FY2017 | Jul 31, 2016 | $104.00M | Oct 16, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jul 31, 2015 | $6.35M | Oct 14, 2015 |
| FY2014 | Jul 31, 2014 | $6.62M | Oct 14, 2014 |
| FY2014 | Jul 31, 2013 | $7.16M | Oct 14, 2014 |
| FY2013 | Jul 31, 2012 | $30.28M | Oct 15, 2013 |
| FY2012 | Jul 31, 2011 | $30.18M | Nov 9, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 3 | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | 2 | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | 1 | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | 1 | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | 3 | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | 0 | Oct 14, 2022 |
| FY2019 | Jul 31, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Apr 30, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Jan 31, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Oct 31, 2018 | 0 | Oct 11, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 3 | Sep 29, 2025 |
| FY2025 | Jul 31, 2024 | 2 | Sep 29, 2025 |
| FY2025 | Jul 31, 2023 | 1 | Sep 29, 2025 |
| FY2024 | Jul 31, 2022 | 1 | Oct 15, 2024 |
| FY2023 | Jul 31, 2021 | 3 | Oct 16, 2023 |
| FY2022 | Jul 31, 2020 | 0 | Oct 14, 2022 |
| FY2019 | Jul 31, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Apr 30, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Jan 31, 2019 | 0 | Oct 11, 2019 |
| FY2019 | Oct 31, 2018 | 0 | Oct 11, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jul 31, 2018 | $13.94M | Oct 11, 2019 |
| FY2019 | Jul 31, 2017 | $17.87M | Oct 11, 2019 |
| FY2018 | Jul 31, 2016 | $17.36M | Oct 15, 2018 |
| FY2017 | Jul 31, 2015 | $47.59M | Oct 16, 2017 |
| FY2016 | Jul 31, 2014 | $13.64M | Oct 14, 2016 |
| FY2015 | Jul 31, 2013 | $17.12M | Oct 14, 2015 |
| FY2014 | Jul 31, 2012 | $15.01M | Oct 14, 2014 |
| FY2013 | Jul 31, 2011 | $15.18M | Oct 15, 2013 |